-
Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study
Sep 9, 2025, 16:22 PM -
Framing Matters! Implications of Loss Aversion for Communicating Benefits to Patients in Preference Studies (and Beyond)
Sep 9, 2025, 16:22 PM -
Hereditary Transthyretin Amyloidosis (ATTRv) Below the Age of 70 Healthcare Resource Utilization and Mortality
Sep 9, 2025, 16:22 PM -
Development and Implementation of a Health and Well-being Index to Inform Risk Management and Patient Engagement in a Colombian Health Insurance Plan
Sep 9, 2025, 16:22 PM -
Estimating the Age- and Sex-Standardized Prevalence and Incidence of Depression and Anxiety in UK Adults Using the THIN Database
Sep 9, 2025, 16:22 PM -
Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia Among United States Medicare Beneficiaries
Sep 9, 2025, 16:22 PM -
A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants
Sep 9, 2025, 16:22 PM -
Epidemiology of Breast Cancer in France
Sep 9, 2025, 16:22 PM -
Comparative Clinical Effectiveness in Skin Cancer: Lessons From HTA Decision Making in EU4, UK, and Australia
Sep 9, 2025, 16:22 PM -
Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends
Sep 9, 2025, 16:22 PM -
Efficacy and Safety of Nalbuphine Compared With Analgesics for Moderate to Severe Postoperative Pain: A Systematic Review and Network Meta-Analysis
Sep 9, 2025, 16:22 PM -
Clinical Outcomes In HTA Appraisal Reports Of Oncology Medicines In Portugal: A Cross-Sectional Analysis
Sep 9, 2025, 16:22 PM -
An Economic Evaluation to Inform the Use of Enhanced Influenza Vaccines for Those Aged 65 Years and Older in the Seasonal Influenza Vaccination Program in Ireland
Sep 9, 2025, 16:22 PM -
Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review
Sep 9, 2025, 16:22 PM -
The Value of Rare Pediatric Disease Designation Program for Decision Making by Drug Developers
Sep 9, 2025, 16:22 PM -
The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses
Sep 9, 2025, 16:22 PM -
Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model
Sep 9, 2025, 16:22 PM -
Definitive Staging and Perioperative Treatment for Resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): A UK Perspective
Sep 9, 2025, 16:22 PM -
Effect of the Inflation Reduction Act on Drug Innovation
Sep 9, 2025, 16:22 PM -
Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework
Sep 9, 2025, 16:22 PM
